Literature DB >> 18586450

Involvement of ERK/MAPK pathway in megakaryocytic differentiation of K562 cells induced by 3-hydrogenkwadaphnin.

Azadeh Meshkini1, Razieh Yazdanparast.   

Abstract

Since differentiation-induction therapy represents an attractive strategy for treatment of a wide range of malignancies, universal efforts have been devoted to find new and potent differentiation inducers devoid of general toxicities. In that respect, 3-hydrogenkwadaphnin (3-HK), a novel daphnane-type diterpene ester from Dendrostellera lessertii (Thymelaeaceae), was found to be an effective inducer of megakaryocytic differentiation in chronic myelogenous leukemia (CML) K562 cells without any adverse effects on normal cells [Moosavi, M.A., Yazdanparast, R., Sanati, M.H., Nejad, A.S., 2005. 3-Hydrogenkwadaphnin targets inosine 5'-monophosphate dehydrogenase and triggers post-G1 arrest apoptosis in human leukemia cell lines. International Journal of Biochemistry and Cell Biology 37, 2366-2379]. In this study, we found that inhibition of cellular replication and maturation, induced by the drug, are dependent upon ERK/MAPK activation. Inhibition of MEK activity by PD98059 reversed the growth arrest, decreased adhesive properties, induction of polyploidization and blocked the expression of GPIIb integrin, induced by 3-HK. Immunoblot analyses also showed that 3-HK-induced sustained activation of ERK1/2 from early exposure times, before the onset of differentiation, up to 96 h. Moreover, our results revealed that cyclin D1 and p21(Cip/WAF1) were increased during differentiation. Consequently, it is concluded that up-regulation of cyclin D1, accompanied by the persistent activation of ERK/MAPK, is involved in the megakaryocytic differentiation of K562 cells under the influence of 3-HK.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586450     DOI: 10.1016/j.tiv.2008.05.005

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  8 in total

1.  Effects of lentivirus mediated STAT3 silencing on human chronic myeloid leukemia cells and leukemia mice.

Authors:  Xinyan Jia; Wenzhong Yang; Jia Han; Hong Xiong
Journal:  Int J Clin Exp Med       Date:  2014-11-15

2.  Protein-arginine methyltransferase 1 suppresses megakaryocytic differentiation via modulation of the p38 MAPK pathway in K562 cells.

Authors:  Yuan-I Chang; Wei-Kai Hua; Chao-Ling Yao; Shiaw-Min Hwang; Yi-Chi Hung; Chih-Jen Kuan; Jiun-Shyang Leou; Wey-Jinq Lin
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

3.  Differential behaviors of trastuzumab-sensitive and -resistant SKBR3 cells treated with menadione reveal the involvement of Notch1/Akt/FOXO1 signaling elements.

Authors:  Soraya Sajadimajd; Razieh Yazdanparast
Journal:  Mol Cell Biochem       Date:  2015-06-27       Impact factor: 3.396

4.  Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2.

Authors:  Jian-Guo Ren; Pankaj Seth; Peter Everett; Clary B Clish; Vikas P Sukhatme
Journal:  PLoS One       Date:  2010-09-02       Impact factor: 3.240

5.  Proteomic and systems biology analysis of monocytes exposed to securinine, a GABA(A) receptor antagonist and immune adjuvant.

Authors:  Matt Shipman; Kirk Lubick; David Fouchard; Rajani Guram; Paul Grieco; Mark Jutila; Edward A Dratz
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

6.  MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation.

Authors:  W Zhao; H He; K Ren; B Li; H Zhang; Y Lin; R-G Shao
Journal:  Blood Cancer J       Date:  2013-03-29       Impact factor: 11.037

7.  Lapatinib induces autophagic cell death and differentiation in acute myeloblastic leukemia.

Authors:  Yu-Jen Chen; Li-Wen Fang; Wen-Chi Su; Wen-Yi Hsu; Kai-Chien Yang; Huey-Lan Huang
Journal:  Onco Targets Ther       Date:  2016-07-20       Impact factor: 4.147

8.  Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma.

Authors:  Selami K Toprak; Klara Dalva; Merih Kızıl Cakar; Nazmiye Kurşun; Meral Beksaç
Journal:  Turk J Haematol       Date:  2011-04-28       Impact factor: 1.831

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.